These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15542671)

  • 1. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.
    Ruckwardt TJ; Tikhonov I; Berg S; Hatfield GS; Chandra A; Chandra P; Gilliam B; Redfield RR; Gallo RC; Pauza CD
    J Virol; 2004 Dec; 78(23):13190-6. PubMed ID: 15542671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
    Rodman TC; To SE; Hashish H; Manchester K
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
    Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
    J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
    Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
    J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.
    Goldstein G; Tribbick G; Manson K
    Vaccine; 2001 Feb; 19(13-14):1738-46. PubMed ID: 11166899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length HIV-1 Tat protein necessary for a vaccine.
    Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
    Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR.
    Tosi G; Meazza R; De Lerma Barbaro A; D'Agostino A; Mazza S; Corradin G; Albini A; Noonan DM; Ferrini S; Accolla RS
    Eur J Immunol; 2000 Apr; 30(4):1120-6. PubMed ID: 10760801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
    Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
    Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals.
    Belliard G; Romieu A; Zagury JF; Dali H; Chaloin O; Le Grand R; Loret E; Briand JP; Roques B; Desgranges C; Muller S
    Vaccine; 2003 Jul; 21(23):3186-99. PubMed ID: 12804847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains.
    Tähtinen M; Ranki A; Valle SL; Ovod V; Krohn K
    Biomed Pharmacother; 1997; 51(10):480-7. PubMed ID: 9863510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
    Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
    Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope.
    Rodman TC; Pruslin FH; To SE; Winston R
    J Exp Med; 1992 May; 175(5):1247-53. PubMed ID: 1373758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers.
    Noonan DM; Gringeri A; Meazza R; Rosso O; Mazza S; Muça-Perja M; Le Buanec H; Accolla RS; Albini A; Ferrini S
    J Acquir Immune Defic Syndr; 2003 May; 33(1):47-55. PubMed ID: 12792355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.